News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The product will be launched in March 2024
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Cipla completes transfer of Generics Business Undertaking
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Subscribe To Our Newsletter & Stay Updated
